Opinion|Videos|April 16, 2024
Assessing the Cost-Effectiveness of Prescription Digital Therapeutics
Mahsa Salsabili, PharmD, PhD, underscores the potential cost-effectiveness of treatment through the adoption of prescription digital therapeutics, while acknowledging that additional evidence is required to conclusively determine their cost-effectiveness.
Advertisement
Episodes in this series
Advertisement
Related to this article
Findings from an analysis of IQVIA claims data show a prevalence rate that is five times lower than previous reports. Some of the discrepancy could be chalked up to the difference between using claims data instead of self-reporting by survey respondents.
Epic Research finds over half of children with type 1 diabetes miss autoantibody testing, risking misdiagnosis and limiting early treatment options like Tzield.
Higher MRI-measured liver disease activity was linked to lower quality of life and more anxiety and activity problems in 802 adults with suspected MASLD/MASH in Europe.
Teen boys with obesity and lower baseline fitness were less likely to see MASLD resolve during a lifestyle program, a Belgian study found.
MassHealth's Katelyn Meyer, Pharm.D., says mandatory coverage, young patients and an unpredictable FDA make planning for new specialty drugs a challenge.
A truly transparent PBM arrangement starts with full disclosure of direct and indirect compensation.
The rule requires pharmacy benefit managers to disclose rebates and discounts, money made from spread pricing and incentives for formulary placement.
As pulmonary fibrosis treatment options grow, Rachael Prusi of Prime Therapeutics says health plans should lean on guidelines and strong case management.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
How common is atopic dermatitis in the US? Not nearly as common as other research has shown, according to this study
2
Medicaid can't opt out of gene therapies, so planning matters more, says Katelyn Meyer, Pharm.D. | AMCP Nexus 2026
3
Lower fitness tied to persistent fatty liver disease in teen boys with obesity
4
Updated HIV treatment guidelines address payer barriers and add Bixlenvo
5